A Phase II Study of Implants of Encapsulated Human NTC-201 Cells Releasing Ciliary Neurotrophic Factor (CNTF), in Participants With Visual Acuity Impairment Associated With Atrophic Macular Degeneration
Latest Information Update: 02 Apr 2025
At a glance
- Drugs Revakinagene taroretcel (Primary)
- Indications Dry macular degeneration
- Focus Therapeutic Use
- Sponsors GNT Pharma
Most Recent Events
- 31 Oct 2014 New trial record